Format

Send to

Choose Destination
J Alzheimers Dis. 2016 Jul 2;53(4):1365-73. doi: 10.3233/JAD-160238.

Evolution of the Antidepressant Prescribing in Alzheimer's Disease and Related Disorders Between 2010 and 2014: Results from the French National Database on Alzheimer's Disease (BNA).

Author information

1
EA Cobtek, University of Nice Sophia-Antipolis, Nice, France.
2
Research Memory Centre, Nice University Hospital, Nice, France.
3
Department of Public Health, L'Archet Hospital, Nice University Hospital, Nice, France.

Abstract

BACKGROUND:

Safety warnings from health authorities are currently intended to limit the use of psychotropic agents in dementia-related conditions. Evidence concerning the use of antidepressants in dementia is, however, scarce and contradictory.

OBJECTIVE:

To evaluate antidepressant use among individuals with Alzheimer's disease (AD) and related disorders in the French population between 2010 and 2014.

METHOD:

Antidepressant prescriptions in individuals with AD, mixed dementia (MD), and vascular dementia (VaD) in the French National Alzheimer Database between 2010 and 2014 were analyzed (N = 199,544).

RESULTS:

Multivariate analysis showed an annual significant increase (p < 0.001) in the prescription rate of antidepressants from 26% (2010) to 31% (2014), and identified female gender, younger age, higher education, living in long-term facilities, more severe cognitive decline, and presence of vascular signs (VaD and MD) as associated factors for antidepressant prescribing.

CONCLUSION:

The annual increase of antidepressant prescribing among individuals with AD, MD, and VaD in French specialized settings may be partially related to the lack of current valuable medications for dementia-related behavioral symptoms.

KEYWORDS:

Alzheimer’s disease; antidepressant; dementia; psychotropic medication

PMID:
27392860
DOI:
10.3233/JAD-160238
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for IOS Press
Loading ...
Support Center